Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Purchased by Barclays PLC

Barclays PLC grew its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 349.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 184,189 shares of the company’s stock after acquiring an additional 143,184 shares during the quarter. Barclays PLC’s holdings in Maravai LifeSciences were worth $1,531,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Maravai LifeSciences during the 2nd quarter valued at $32,000. Venturi Wealth Management LLC acquired a new stake in shares of Maravai LifeSciences in the third quarter valued at $47,000. Custom Index Systems LLC bought a new position in Maravai LifeSciences during the third quarter valued at about $97,000. Y Intercept Hong Kong Ltd acquired a new position in Maravai LifeSciences during the third quarter worth about $105,000. Finally, Headlands Technologies LLC raised its position in Maravai LifeSciences by 205.9% in the second quarter. Headlands Technologies LLC now owns 14,935 shares of the company’s stock worth $107,000 after acquiring an additional 10,053 shares in the last quarter. Institutional investors own 50.25% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRVI. Guggenheim began coverage on shares of Maravai LifeSciences in a research report on Thursday, December 19th. They set a “neutral” rating for the company. Royal Bank of Canada reduced their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Robert W. Baird reduced their price objective on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, Wolfe Research started coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $10.28.

Maravai LifeSciences Trading Down 2.0 %

Shares of Maravai LifeSciences stock opened at $5.50 on Friday. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -3.35 and a beta of -0.07. Maravai LifeSciences Holdings, Inc. has a 1 year low of $4.28 and a 1 year high of $11.56. The company’s fifty day simple moving average is $6.01 and its 200-day simple moving average is $7.52. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Insider Activity at Maravai LifeSciences

In related news, insider Carl Hull acquired 175,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $5.64 per share, with a total value of $987,000.00. Following the completion of the acquisition, the insider now owns 175,000 shares in the company, valued at $987,000. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.63% of the stock is currently owned by corporate insiders.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.